
    
      Secondary endpoints are to evaluate:

        -  the objective response rate (RR) of the combination;

        -  the toxicity and the safety profile of the combination;

        -  the duration of response (RD) and time to treatment failure (TTF);

        -  the overall survival (OS)

        -  RR, TTP and OS according to baseline plasma VEGF levels (introduced with Amendment 1
           dated 8/11/2007)
    
  